Susanne Max Radke

Medical Advisor, Molecular Oncologist, Healthcare Consultant, Cancer Patient Friend

[Protect Kamala Harris ✊ @DisavowTrump20]

RETWEET if you stand with the Obamas against Trump’s racist attacks!

[The Tennessee Holler @TheTNHoller]

OBAMA: “People make excuses for him. They say he’s not serious. Everything a president says is serious!”🔥

[Arndt Vogel @ArndtVogel]

🔥hot off the press
👉ESMO-MCBS 2.0 Scorecards now available
🧐Do you agree with the proposed benefit?
👇Check them out for Hepatocellular Carcinoma
https://t.co/PSWyksRUMB
@myESMO @ILCAnews @EASLedu

[Arndt Vogel @ArndtVogel]

🔥hot off the press
👉ESMO-MCBS 2.0 Scorecards now available
🧐Do you agree with the proposed benefit?
👇Check them out for Cholangiocarcinoma
https://t.co/PSWyksRUMB
@myESMO @ILCAnews @EASLedu

[Keith Siau @drkeithsiau]

How to write a literature review 🖋️💡

[Arndt Vogel @ArndtVogel]

Battle of the biopsies: Role of tissue and liquid biopsy in
hepatocellular carcinoma
@JHepatology
https://t.co/rnH66nOK3R
👏Very comprehensive review on liquid and tissue biopsy in HCC
😅It's not a battle, it complements each other ...
@myESMO @EASLnews @ILCAnews #livertwitter

[Kohei shitara @KoheiShitara]

Pleased to share PAGA guideline for #gastriccancer. Really appreciate Asian & European experts @LizzySmyth1 @tfleitask @GPentheroudakis @AndresC27622123 who joined the discussion. Thank you @myESMO and @JSMO_official for excellent support. https://t.co/D1XPpUP1Oc

[Kohei shitara @KoheiShitara]

Happy to share review of zolbetuximab for #gastriccancer. Regulatory approval still awaited.
https://t.co/VV2SFvHztW

[Arndt Vogel @ArndtVogel]

🔥Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing
Cancer Treatment Reviews
https://t.co/iSsffcsvvr
👉Understand all the advantages & disadvantages of hybrid capture vs amplicon-based enrichment and DNA vs RNA based NGS
@myESMO @EASLedu @ILCAnews @curecc #livertwitter

[Susanne Max Radke @MedInContext]

@StephenVLiu @HosseinBorghaei @DrSteveMartin Happy Birthday! 🎁

[Susanne Max Radke @MedInContext]

@rachnatshroff @UAZHemeOnc @UAZCancer @UAZMedTucson @UAZHealth @UAZWIMSTucson Congratulations 🍾

[Lizzy Smyth @LizzySmyth1]

📢📢 Less than a week to go until #ESMO23⏳

@myESMO asked the Upper GI track chair 👩‍⚕️ to share some upcoming highlights below ⬇️

Whether you're on a ✈️, 🚝 or watching 💻 Friday 2pm CET is when the transformative Upper GI starts...see you in Madrid....

[Susanne Max Radke @MedInContext]

@LizzySmyth1 @myESMO @FlorianLordick @DrAngelaLamarca @MagnusNsurgonc @YJanjigianMD @KoheiShitara @tfleitask @RadkaObermanno1 @ldawsonmd @LorenzaRimassa Thank you! Looking forward to seeing you in Madrid as well!

[Dr Riyaz Shah @DrRiyazShah]

DESTINY LUNG 02: #WCLC23 updated data; impressive activity but remain concerned about ILD.

[Benjamin Besse @BenjaminBesseMD]

Flaura-2: escalation from osi to osi + CT makes sense in pts with ‘hard to treat’ EGFRmut NSCLC: exon 21, brain mets, and probably if symptoms/high tumor burden since PS1 pts derive more benefit than PS0. ~5X more Gr3 AEs & no signal in OS: not obvious in all comers. #WCLC2023

[Jordi Remon @JordiRemon]

🎉FLAURA2 in EGFR-mut aNSCLC is➕
Escalating 🏔️ ttx in blinded way provides toxicity, not all need intensive ttx. CT-DNA status before EGFR TKI (data from FLAURA) is poor prog marker.These are the patients who may benefit of intense ttx.Only more to some pts,not for all #WCLC23

[Jordi Remon @JordiRemon]

Repotrectinib seems a potent drug in TKI naïve ROS1➕ aNSCLC. Hwv, data ~ to Taletrectinib.Challenge is pre-treated patients and repotrectinib data looks similar to others but this drug acts against acquired G2032 ROS1 mut (not lorlatinib). Genomic profile at PD relevant #WCLC23

[Sanjay Popat @DrSanjayPopat]

TRIDENT trial repotrectinib update. Impressive ORR, DOR and icPFS in ROS1 TKI naive. High activity post 1 TKI. Pleased to see responses in G2032R #WCLC23

[Sanjay Popat @DrSanjayPopat]

Dr. Clarke: CODEBREAK101 soto960mg+carbo-pem: (SCARLET ORR 89%). Mainly cytopenias as expected. Higher AEs 2nd line(post IO). ORR 65% front line and 54% 2nd line. Await DOR and PFS #WCLC23

[Dr Riyaz Shah @DrRiyazShah]

Loved this PROTAC strategy for “undrugable” targets. Really interesting early data that the concept works using G12D model #WCLC23